

## FRANCE, 3 registries (1990-2012)

	Number of cases							Percentage				Incidence rates per million person-years								MV % 0-19	DCO % 0-19	
	Age group							0-14		0-19		Age-specific					Cumulative					
	0	1-4	5-9	10-14	15-19	0-14	0-19	All	Group	All	Group	0	1-4	5-9	10-14	15-19	0-14	ASR	0-19			0-14
<b>I LEUKAEMIA</b>	9	37	35	29	32	110	142	32.1	100.0	28.8	100.0	44.6	45.3	33.3	26.8	30.2	36.0	34.7	527	677	97.9	0.7
a. Lymphoid	1	29	22	21	15	73	88	21.3	66.4	17.8	62.0	5.0	35.5	20.9	19.4	14.1	23.8	21.6	349	420	100.0	0.0
b. Acute myeloid	3	2	8	8	7	21	28	6.1	19.1	5.7	19.7	14.9	2.5	7.6	7.4	6.6	6.5	6.5	100	133	89.3	3.6
c. CMD	0	4	2	0	6	6	12	1.7	5.5	2.4	8.5	-	4.9	1.9	-	5.7	2.1	2.9	29	57	100.0	0.0
d. MDS & other	3	0	1	0	2	4	6	1.2	3.6	1.2	4.2	14.9	-	1.0	-	1.9	1.4	1.5	19	29	100.0	0.0
e. Unspecified	2	2	2	0	2	6	8	1.7	5.5	1.6	5.6	9.9	2.5	1.9	-	1.9	2.1	2.1	29	39	100.0	0.0
<b>II LYMPHOMA &amp; RELATED</b>	1	4	9	19	27	33	60	9.6	100.0	12.2	100.0	5.0	4.9	8.6	17.6	25.5	9.8	13.3	155	283	100.0	0.0
a. Hodgkin	1	0	3	10	18	14	32	4.1	42.4	6.5	53.3	5.0	-	2.9	9.2	17.0	4.0	6.9	65	150	100.0	0.0
b. Non-Hodgkin except BL	0	2	5	7	8	14	22	4.1	42.4	4.5	36.7	-	2.5	4.8	6.5	7.5	4.2	4.9	66	104	100.0	0.0
c. Burkitt (BL)	0	2	1	2	0	5	5	1.5	15.2	1.0	8.3	-	2.5	1.0	1.8	-	1.6	1.2	24	24	100.0	0.0
d. Lymphoreticular	0	0	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
e. Unspecified	0	0	0	0	1	0	1	-	-	0.2	1.7	-	-	-	-	0.9	-	0.2	-	5	100.0	0.0
<b>III CNS NEOPLASMS †</b>	5	24	19	18	18	66	84	19.2	100.0	17.0	100.0	24.8	29.4	18.1	16.6	17.0	21.7	20.6	316	401	71.4	0.0
a. Ependymoma	1	8	1	1	2	11	13	3.2	16.7	2.6	15.5	5.0	9.8	1.0	0.9	1.9	4.0	3.5	54	63	92.3	0.0
b. Astrocytoma	0	6	7	3	3	16	19	4.7	24.2	3.9	22.6	-	7.4	6.7	2.8	2.8	5.2	4.7	77	91	94.7	0.0
c. CNS embryonal	0	6	9	0	2	15	17	4.4	22.7	3.4	20.2	-	7.4	8.6	-	1.9	5.0	4.3	72	82	88.2	0.0
d. Other gliomas	0	1	0	3	1	4	5	1.2	6.1	1.0	6.0	-	1.2	-	2.8	0.9	1.2	1.1	19	23	40.0	0.0
e. Other specified	1	0	1	7	8	9	17	2.6	13.6	3.4	20.2	5.0	-	1.0	6.5	7.5	2.6	3.7	42	80	76.5	0.0
f. Unspecified CNS	3	3	1	4	2	11	13	3.2	16.7	2.6	15.5	14.9	3.7	1.0	3.7	1.9	3.7	3.3	53	62	0.0	0.0
<b>IV NEUROBLASTOMA</b>	2	9	6	3	0	20	20	5.8	100.0	4.1	100.0	9.9	11.0	5.7	2.8	-	6.8	5.3	96	96	80.0	0.0
a. (Ganglio)neuroblastoma	2	9	6	1	0	18	18	5.2	90.0	3.7	90.0	9.9	11.0	5.7	0.9	-	6.3	4.9	87	87	83.3	0.0
b. Peripheral nervous	0	0	0	2	0	2	2	0.6	10.0	0.4	10.0	-	-	-	1.8	-	0.5	0.4	9	9	50.0	0.0
<b>V RETINOBLASTOMA</b>	1	9	0	0	0	10	10	2.9	100.0	2.0	100.0	5.0	11.0	-	-	-	3.8	2.9	49	49	80.0	0.0
<b>VI RENAL TUMOURS</b>	0	11	4	2	5	17	22	5.0	100.0	4.5	100.0	-	13.5	3.8	1.8	4.7	5.9	5.7	82	106	95.5	0.0
a. Nephroblastoma	0	11	4	2	1	17	18	5.0	100.0	3.7	81.8	-	13.5	3.8	1.8	0.9	5.9	4.8	82	87	94.4	0.0
b. Renal carcinoma	0	0	0	0	4	0	4	-	-	0.8	18.2	-	-	-	-	3.8	-	0.8	-	19	100.0	0.0
c. Unspecified	0	0	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<b>VII HEPATIC TUMOURS</b>	1	1	1	0	1	3	4	0.9	100.0	0.8	100.0	5.0	1.2	1.0	-	0.9	1.1	1.0	15	19	100.0	0.0
a. Hepatoblastoma	1	1	1	0	0	3	3	0.9	100.0	0.6	75.0	5.0	1.2	1.0	-	-	1.1	0.8	15	15	100.0	0.0
b. Hepatic carcinoma	0	0	0	0	1	0	1	-	-	0.2	25.0	-	-	-	0.9	-	-	0.2	-	5	100.0	0.0
c. Unspecified	0	0	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<b>VIII BONE TUMOURS</b>	0	2	4	12	11	18	29	5.2	100.0	5.9	100.0	-	2.5	3.8	11.1	10.4	5.2	6.4	84	136	86.2	0.0
a. Osteosarcoma	0	1	2	9	5	12	17	3.5	66.7	3.4	58.6	-	1.2	1.9	8.3	4.7	3.4	3.7	56	80	100.0	0.0
b. Chondrosarcoma	0	0	1	2	2	3	5	0.9	16.7	1.0	17.2	-	-	1.0	1.8	1.9	0.8	1.1	14	23	100.0	0.0
c. Ewing & related	0	0	1	0	3	1	4	0.3	5.6	0.8	13.8	-	-	1.0	-	2.8	0.3	0.9	5	19	75.0	0.0
d. Other specified	0	0	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
e. Unspecified	0	1	0	1	1	2	3	0.6	11.1	0.6	10.3	-	1.2	-	0.9	0.9	0.6	0.7	10	14	0.0	0.0
<b>IX SOFT TISSUE SARCOMA</b>	4	8	11	11	14	34	48	9.9	100.0	9.7	100.0	19.8	9.8	10.5	10.2	13.2	10.9	11.4	162	228	100.0	0.0
a. Rhabdomyosarcoma	1	5	7	2	4	15	19	4.4	44.1	3.9	39.6	5.0	6.1	6.7	1.8	3.8	5.0	4.7	72	91	100.0	0.0
b. Fibrosarcoma	1	0	0	1	2	2	4	0.6	5.9	0.8	8.3	5.0	-	-	0.9	1.9	0.6	0.9	10	19	100.0	0.0
c. Kaposi sarcoma	1	0	0	0	0	1	1	0.3	2.9	0.2	2.1	5.0	-	-	-	-	0.4	0.3	5	5	100.0	0.0
d. Other specified	0	2	3	6	8	11	19	3.2	32.4	3.9	39.6	-	2.5	2.9	5.5	7.5	3.3	4.2	52	90	100.0	0.0
e. Unspecified	1	1	1	2	0	5	5	1.5	14.7	1.0	10.4	5.0	1.2	1.0	1.8	-	1.6	1.2	24	24	100.0	0.0
<b>X GERM CELL TUMOURS</b>	4	3	3	8	16	18	34	5.2	100.0	6.9	100.0	19.8	3.7	2.9	7.4	15.1	5.7	7.8	86	161	97.1	0.0
a. CNS germ cell	2	0	1	1	0	4	4	1.2	22.2	0.8	11.8	9.9	-	1.0	0.9	-	1.3	1.0	19	19	75.0	0.0
b. Other extragonadal	1	0	1	0	2	2	4	0.6	11.1	0.8	11.8	5.0	-	1.0	-	1.9	0.7	1.0	10	19	100.0	0.0
c. Gonadal germ cell	1	3	1	6	12	11	23	3.2	61.1	4.7	67.6	5.0	3.7	1.0	5.5	11.3	3.4	5.2	52	109	100.0	0.0
d. Gonadal carcinoma	0	0	0	0	1	0	1	-	-	0.2	2.9	-	-	-	-	0.9	-	0.2	-	5	100.0	0.0
e. Unspecified gonadal	0	0	0	1	1	1	2	0.3	5.6	0.4	5.9	-	-	-	0.9	0.9	0.3	0.4	5	9	100.0	0.0
<b>XI CARCINOMA &amp; MELANOMA</b>	0	1	1	10	23	12	35	3.5	100.0	7.1	100.0	-	1.2	1.0	9.2	21.7	3.4	7.5	56	164	100.0	0.0
a. Adrenocortical	0	0	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
b. Thyroid	0	0	0	2	12	2	14	0.6	16.7	2.8	40.0	-	-	-	1.8	11.3	0.5	3.0	9	66	100.0	0.0
c. Nasopharyngeal	0	0	0	3	1	3	4	0.9	25.0	0.8	11.4	-	-	-	2.8	0.9	0.8	0.8	14	19	100.0	0.0
d. Melanoma	0	0	0	0	2	0	2	-	-	0.4	5.7	-	-	-	-	1.9	-	0.4	-	9	100.0	0.0
e. Skin carcinoma	0	0	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
f. Other & unspecified	0	1	1	5	8	7	15	2.0	58.3	3.0	42.9	-	1.2	1.0	4.6	7.5	2.0	3.3	33	71	100.0	0.0
<b>XII OTHER &amp; UNSPECIFIED</b>	0	1	1	0	3	2	5	0.6	100.0	1.0	100.0	-	1.2	1.0	-	2.8	0.7	1.2	10	24	20.0	0.0
a. Other specified	0	0	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
b. Other unspecified	0	1	1	0	3	2	5	0.6	100.0	1.0	100.0	-	1.2	1.0	-	2.8	0.7	1.2	10	24	20.0	0.0
<b>TOTAL</b>	27	110	94	112	150	343	493	100.0	100.0	100.0	100.0	133.7	134.8	89.5	103.6	141.5	111.0	117.9	1638	2345	91.3	0.2

† includes 31 non-malignant

Please consult the quality indicators for the constituent registries

## FRANCE, 3 registries (1990-2012)

	Males										M/F ratio		Females									
	Number of cases in age groups												Number of cases in age groups									
	0	1-4	5-9	10-14	15-19	0-14	0-19	0-14	0-19	0-14	0-19	0	1-4	5-9	10-14	15-19	0-14	0-19	0-14	0-19		
<b>I LEUKAEMIA</b>	6	24	21	19	21	70	91	45.3	43.9	1.8	1.8	3	13	14	10	11	40	51	26.5	25.3		
a. Lymphoid	1	18	14	13	12	46	58	29.6	28.0	1.7	1.9	0	11	8	8	3	27	30	17.8	15.1		
b. Acute myeloid	2	2	3	6	4	13	17	8.0	7.9	1.6	1.5	1	0	5	2	3	8	11	5.0	5.1		
c. CMD	0	2	1	0	3	3	6	2.1	2.9	1.0	1.0	0	2	1	0	3	3	6	2.2	3.0		
d. MDS & other	2	0	1	0	0	3	3	2.1	1.6	3.0	1.0	1	0	0	0	2	1	3	0.8	1.5		
e. Unspecified	1	2	2	0	2	5	7	3.5	3.5	5.0	7.0	1	0	0	0	0	1	1	0.8	0.6		
<b>II LYMPHOMA &amp; RELATED</b>	1	3	6	14	13	24	37	14.0	16.3	2.7	1.6	0	1	3	5	14	9	23	5.4	10.2		
a. Hodgkin	1	0	2	8	10	11	21	6.2	9.0	3.7	1.9	0	0	1	2	8	3	11	1.7	4.8		
b. Non-Hodgkin except BL	0	1	3	4	3	8	11	4.7	4.9	1.3	1.0	0	1	2	3	5	6	11	3.6	5.0		
c. Burkitt (BL)	0	2	1	2	0	5	5	3.2	2.5	-	-	0	0	0	0	0	0	0	-	-		
d. Lymphoreticular	0	0	0	0	0	0	0	-	-	-	-	0	0	0	0	0	0	0	-	-		
e. Unspecified	0	0	0	0	0	0	0	-	-	-	0.0	0	0	0	0	1	0	1	-	0.4		
<b>III CNS NEOPLASMS †</b>	4	15	9	6	10	34	44	22.9	21.9	1.1	1.1	1	9	10	12	8	32	40	20.5	19.3		
a. Ependymoma	1	5	0	0	2	6	8	4.5	4.3	1.2	1.6	0	3	1	1	0	5	5	3.5	2.7		
b. Astrocytoma	0	4	2	2	3	8	11	5.3	5.3	1.0	1.4	0	2	5	1	0	8	8	5.2	4.0		
c. CNS embryonal	0	5	6	0	0	11	11	7.4	5.7	2.8	1.8	0	1	3	0	2	4	6	2.6	2.9		
d. Other gliomas	0	1	0	1	1	2	3	1.3	1.4	1.0	1.5	0	0	0	2	0	2	2	1.1	0.8		
e. Other specified	0	0	1	1	2	2	4	1.1	1.7	0.3	0.3	1	0	0	6	6	7	13	4.0	5.7		
f. Unspecified CNS	3	0	0	2	2	5	7	3.3	3.4	0.8	1.2	0	3	1	2	0	6	6	4.0	3.1		
<b>IV NEUROBLASTOMA</b>	1	5	3	3	0	12	12	7.9	6.1	1.5	1.5	1	4	3	0	0	8	8	5.7	4.4		
a. (Ganglio)neuroblastoma	1	5	3	1	0	10	10	6.9	5.3	1.3	1.3	1	4	3	0	0	8	8	5.7	4.4		
b. Peripheral nervous	0	0	0	2	0	2	2	1.1	0.8	-	-	0	0	0	0	0	0	0	-	-		
<b>V RETINOBLASTOMA</b>	1	7	0	0	0	8	8	6.0	4.6	4.0	4.0	0	2	0	0	0	2	2	1.5	1.2		
<b>VI RENAL TUMOURS</b>	0	5	1	1	4	7	11	4.9	5.5	0.7	1.0	0	6	3	1	1	10	11	7.0	5.9		
a. Nephroblastoma	0	5	1	1	1	7	8	4.9	4.2	0.7	0.8	0	6	3	1	0	10	10	7.0	5.5		
b. Renal carcinoma	0	0	0	0	3	0	3	-	1.3	-	3.0	0	0	0	0	1	0	1	-	0.4		
c. Unspecified	0	0	0	0	0	0	0	-	-	-	-	0	0	0	0	0	0	0	-	-		
<b>VII HEPATIC TUMOURS</b>	0	1	0	0	0	1	1	0.7	0.6	0.5	0.3	1	0	1	0	1	2	3	1.4	1.5		
a. Hepatoblastoma	0	1	0	0	0	1	1	0.7	0.6	0.5	0.5	1	0	1	0	0	2	2	1.4	1.1		
b. Hepatic carcinoma	0	0	0	0	0	0	0	-	-	-	0.0	0	0	0	0	1	0	1	-	0.4		
c. Unspecified	0	0	0	0	0	0	0	-	-	-	-	0	0	0	0	0	0	0	-	-		
<b>VIII BONE TUMOURS</b>	0	2	3	6	9	11	20	6.5	8.8	1.6	2.2	0	0	1	6	2	7	9	3.9	3.9		
a. Osteosarcoma	0	1	2	4	5	7	12	4.1	5.3	1.4	2.4	0	0	0	5	0	5	5	2.7	2.1		
b. Chondrosarcoma	0	0	1	2	1	3	4	1.7	1.7	-	4.0	0	0	0	0	1	0	1	-	0.4		
c. Ewing & related	0	0	0	0	3	0	3	-	1.3	0.0	3.0	0	0	1	0	0	1	1	0.6	0.5		
d. Other specified	0	0	0	0	0	0	0	-	-	-	-	0	0	0	0	0	0	0	-	-		
e. Unspecified	0	1	0	0	0	1	1	0.7	0.6	1.0	0.5	0	0	0	1	1	1	2	0.5	0.9		
<b>IX SOFT TISSUE SARCOMA</b>	3	5	9	5	11	22	33	14.1	15.5	1.8	2.2	1	3	2	6	3	12	15	7.6	7.2		
a. Rhabdomyosarcoma	1	3	5	1	3	10	13	6.6	6.3	2.0	2.2	0	2	2	1	1	5	6	3.3	3.0		
b. Fibrosarcoma	1	0	0	1	2	2	4	1.3	1.8	-	-	0	0	0	0	0	0	0	-	-		
c. Kaposi sarcoma	1	0	0	0	0	1	1	0.7	0.6	-	-	0	0	0	0	0	0	0	-	-		
d. Other specified	0	1	3	2	6	6	12	3.6	5.3	1.2	1.7	0	1	0	4	2	5	7	3.0	3.2		
e. Unspecified	0	1	1	1	0	3	3	1.9	1.5	1.5	1.5	1	0	0	1	0	2	2	1.3	1.0		
<b>X GERM CELL TUMOURS</b>	1	1	0	2	5	4	9	2.6	4.1	0.3	0.4	3	2	3	6	11	14	25	9.0	11.7		
a. CNS germ cell	0	0	0	1	0	1	1	0.5	0.4	0.3	0.3	2	0	1	0	0	3	3	2.2	1.7		
b. Other extragonadal	0	0	0	0	0	0	0	-	-	0.0	0.0	1	0	1	0	2	2	4	1.4	1.9		
c. Gonadal germ cell	1	1	0	1	5	3	8	2.0	3.7	0.4	0.5	0	2	1	5	7	8	15	4.9	6.8		
d. Gonadal carcinoma	0	0	0	0	0	0	0	-	-	-	0.0	0	0	0	0	1	0	1	-	0.4		
e. Unspecified gonadal	0	0	0	0	0	0	0	-	-	0.0	0.0	0	0	0	1	1	1	2	0.5	0.9		
<b>XI CARCINOMA &amp; MELANOMA</b>	0	0	0	3	5	3	8	1.6	3.3	0.3	0.3	0	1	1	7	18	9	27	5.2	11.8		
a. Adrenocortical	0	0	0	0	0	0	0	-	-	-	-	0	0	0	0	0	0	0	-	-		
b. Thyroid	0	0	0	0	2	0	2	-	0.8	0.0	0.2	0	0	0	2	10	2	12	1.1	5.2		
c. Nasopharyngeal	0	0	0	1	1	1	2	0.5	0.8	0.5	1.0	0	0	0	2	0	2	2	1.1	0.8		
d. Melanoma	0	0	0	0	0	0	0	-	-	-	0.0	0	0	0	0	2	0	2	-	0.9		
e. Skin carcinoma	0	0	0	0	0	0	0	-	-	-	-	0	0	0	0	0	0	0	-	-		
f. Other & unspecified	0	0	0	2	2	2	4	1.1	1.7	0.4	0.4	0	1	1	3	6	5	11	3.0	4.9		
<b>XII OTHER &amp; UNSPECIFIED</b>	0	1	0	0	2	1	3	0.7	1.4	1.0	1.5	0	0	1	0	1	1	2	0.6	0.9		
a. Other specified	0	0	0	0	0	0	0	-	-	-	-	0	0	0	0	0	0	0	-	-		
b. Other unspecified	0	1	0	0	2	1	3	0.7	1.4	1.0	1.5	0	0	1	0	1	1	2	0.6	0.9		
<b>TOTAL</b>	17	69	52	59	80	197	277	127.3	132.1	1.3	1.3	10	41	42	53	70	146	216	94.3	103.2		

† includes 17 non-malignant in males and 14 non-malignant in females

Please consult the quality indicators for the constituent registries

## FRANCE, 3 registries (1990-2012)

	Age group	Males	Females
Person-years	0	102 218	99 695
	1-4	413 914	402 161
	5-9	531 176	519 475
	10-14	549 211	532 167
	15-19	537 620	522 616
Total	0-14	1 596 519	1 553 498
	0-19	2 134 139	2 076 114
Average annual population	0-14	69 414	67 543
	0-19	92 789	90 266

Please consult the quality indicators for the constituent registries

## FRANCE, 3 registries (1990-2012)

Registry	Period	Cases	%	Person-years	%
French Guiana	2003-2012	149	30.2	950 976	22.6
Guadeloupe	2008-2012	69	14.0	590 976	14.0
Martinique	1990-2012	275	55.8	2 668 301	63.4
<b>FRANCE</b>	<b>1990-2012</b>	<b>493</b>	<b>100.0</b>	<b>4 210 253</b>	<b>100.0</b>

Please consult the quality indicators for the constituent registries

International Incidence of Childhood Cancer Volume III <http://iicc.iarc.fr/results>

French Guiana  
(2003-2012)Martinique  
(1990-2012)

	French Guiana (2003-2012)			French Guiana (2003-2012)			Martinique (1990-2012)			Martinique (1990-2012)		
	Cases	0-14 M/F	ASR	Cases	0-19 M/F	ASR	Cases	0-14 M/F	ASR	Cases	0-19 M/F	ASR
<b>I LEUKAEMIA</b>	28	3.7	37.5	42	2.8	45.2	69	1.5	36.7	85	1.6	33.5
a. Lymphoid	17	2.4	22.5	23	2.3	24.3	48	1.5	25.7	57	1.9	22.8
b. Acute myeloid	4	.	5.4	8	7.0	8.8	13	1.6	6.2	14	1.3	5.2
c. CMD	0	.	.	1	0.0	1.1	5	0.7	3.0	10	1.0	3.9
d. MDS & other	3	.	4.1	4	3.0	4.3	1	0.0	0.6	2	0.0	0.8
e. Unspecified	4	3.0	5.5	6	5.0	6.6	2	.	1.1	2	.	0.9
<b>II LYMPHOMA &amp; RELATED</b>	7	1.3	9.2	12	1.4	12.9	21	3.2	9.6	39	2.0	13.2
a. Hodgkin	4	1.0	5.1	7	1.3	7.4	10	9.0	4.5	22	3.4	7.3
b. Non-Hodgkin except BL	2	1.0	2.8	3	2.0	3.4	9	1.3	4.0	15	0.9	5.0
c. Burkitt (BL)	1	.	1.3	1	.	1.0	2	.	1.1	2	.	0.9
d. Lymphoreticular	0	.	.	0	.	.	0	.	.	0	.	.
e. Unspecified	0	.	.	1	0.0	1.1	0	.	.	0	.	.
<b>III CNS NEOPLASMS †</b>	25	0.9	33.9	33	0.9	35.4	28	1.2	14.9	37	1.2	14.4
a. Ependymoma	3	.	4.3	4	.	4.5	5	0.7	2.9	6	1.0	2.6
b. Astrocytoma	2	1.0	2.8	2	1.0	2.2	11	0.8	5.6	14	1.3	5.3
c. CNS embryonal	3	0.0	4.0	3	0.0	3.1	9	8.0	5.1	11	2.7	4.6
d. Other gliomas	3	2.0	4.0	4	3.0	4.2	1	0.0	0.4	1	0.0	0.3
e. Other specified	3	0.5	4.0	7	0.2	7.7	2	0.0	0.8	5	0.3	1.6
f. Unspecified CNS	11	0.8	14.9	13	1.2	13.8	0	.	.	0	.	.
<b>IV NEUROBLASTOMA</b>	8	1.7	10.9	8	1.7	8.5	9	1.3	5.1	9	1.3	3.9
a. (Ganglio)neuroblastoma	8	1.7	10.9	8	1.7	8.5	8	1.0	4.6	8	1.0	3.6
b. Peripheral nervous	0	.	.	0	.	.	1	.	0.4	1	.	0.3
<b>V RETINOBLASTOMA</b>	2	.	2.8	2	.	2.2	6	2.0	3.8	6	2.0	2.9
<b>VI RENAL TUMOURS</b>	7	0.8	9.6	10	1.5	10.9	8	0.6	4.3	9	0.5	3.7
a. Nephroblastoma	7	0.8	9.6	8	1.0	8.6	8	0.6	4.3	8	0.6	3.4
b. Renal carcinoma	0	.	.	2	.	2.3	0	.	.	1	0.0	0.3
c. Unspecified	0	.	.	0	.	.	0	.	.	0	.	.
<b>VII HEPATIC TUMOURS</b>	0	.	.	0	.	.	1	0.0	0.6	2	0.0	0.8
a. Hepatoblastoma	0	.	.	0	.	.	1	0.0	0.6	1	0.0	0.5
b. Hepatic carcinoma	0	.	.	0	.	.	0	.	.	1	0.0	0.3
c. Unspecified	0	.	.	0	.	.	0	.	.	0	.	.
<b>VIII BONE TUMOURS</b>	3	2.0	3.8	7	1.3	7.5	13	1.6	6.1	19	2.8	6.6
a. Osteosarcoma	2	1.0	2.5	4	3.0	4.3	9	2.0	4.1	11	2.7	3.8
b. Chondrosarcoma	1	.	1.3	2	1.0	2.1	1	.	0.4	2	.	0.6
c. Ewing & related	0	.	.	0	.	.	1	0.0	0.5	4	3.0	1.3
d. Other specified	0	.	.	0	.	.	0	.	.	0	.	.
e. Unspecified	0	.	.	1	0.0	1.1	2	1.0	1.0	2	1.0	0.8
<b>IX SOFT TISSUE SARCOMA</b>	10	9.0	13.4	11	4.5	11.6	19	1.4	9.7	31	2.1	11.4
a. Rhabdomyosarcoma	3	.	4.1	3	.	3.2	9	1.3	4.8	12	1.4	4.7
b. Fibrosarcoma	1	.	1.4	1	.	1.1	1	.	0.4	3	.	1.0
c. Kaposi sarcoma	1	.	1.4	1	.	1.1	0	.	.	0	.	.
d. Other specified	3	.	4.0	4	3.0	4.2	6	1.0	2.8	13	2.3	4.4
e. Unspecified	2	1.0	2.5	2	1.0	2.0	3	2.0	1.7	3	2.0	1.3
<b>X GERM CELL TUMOURS</b>	5	0.3	7.0	9	0.3	10.0	7	0.8	3.4	16	0.6	5.5
a. CNS germ cell	2	0.0	2.7	2	0.0	2.1	1	.	0.4	1	.	0.3
b. Other extragonadal	1	0.0	1.4	3	0.0	3.4	1	0.0	0.5	1	0.0	0.4
c. Gonadal germ cell	2	1.0	2.8	4	1.0	4.5	5	0.7	2.5	12	0.7	4.2
d. Gonadal carcinoma	0	.	.	0	.	.	0	.	.	1	0.0	0.3
e. Unspecified gonadal	0	.	.	0	.	.	0	.	.	1	0.0	0.3
<b>XI CARCINOMA &amp; MELANOMA</b>	5	0.3	6.4	11	0.2	11.8	5	0.3	2.4	21	0.3	6.9
a. Adrenocortical	0	.	.	0	.	.	0	.	.	0	.	.
b. Thyroid	0	.	.	3	0.0	3.4	1	0.0	0.4	10	0.3	3.2
c. Nasopharyngeal	3	0.5	3.8	4	1.0	4.1	0	.	.	0	.	.
d. Melanoma	0	.	.	1	0.0	1.1	0	.	.	1	0.0	0.3
e. Skin carcinoma	0	.	.	0	.	.	0	.	.	0	.	.
f. Other & unspecified	2	0.0	2.5	3	0.0	3.1	4	0.3	2.0	10	0.4	3.4
<b>XII OTHER &amp; UNSPECIFIED</b>	1	0.0	1.3	4	1.0	4.4	1	.	0.6	1	.	0.5
a. Other specified	0	.	.	0	.	.	0	.	.	0	.	.
b. Other unspecified	1	0.0	1.3	4	1.0	4.4	1	.	0.6	1	.	0.5
<b>TOTAL</b>	101	1.5	135.8	149	1.4	160.4	187	1.4	97.3	275	1.3	103.4

† includes 14 non-malignant in French Guiana 13 non-malignant in Martinique

Please consult the quality indicators for the constituent registries